Mikael Kubista back with new venture after turbulent exit

from us. They followed up by showering us with lawsuits,” he says.

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

New version of ISO 10993-1: the core standard for the biological evaluation of medical devices

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...

The FDA’s new transparency policy (Part 2)

In the second part of our article series on the FDA’s new “radical transparency” initiative, we explore regulatory strategies to navigate the potential impact o...

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

Astra Zeneca nådde fas III-mål med ny blodtrycksbehandling

Astra Zeneca rapporterar nya positiva data för baxdrostat mot svårbehandlat högt blodtryck.

JMP Statistical Discovery

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.

Eli Lilly bygger superdator med techjätte – ska påskynda nya läkemedel

Det amerikanska läkemedelsbolaget Eli Lilly har ingått ett samarbete med techjätten Nvidia för att utveckla en ny AI-superdator som ska påskynda upptäckten och ...

Tablettbehandling minskade återfall i bröstcancer med 30 procent i studie

En ny oral läkemedelskandidat från Roche minskade risken för återfall i bröstcancer med 30 procent i en klinisk studie i sen fas.

Digitaliseringen förändrar vårt sätt att arbeta med ånga

Moderna ångsystem utsätts för större påfrestningar än någonsin tidigare, och även små avvikelser kan få stora konsekvenser för driften. Detta ställer helt nya k...

Swedish team tests Alzheimer antibody for brain imaging

Recent breakthroughs in Alzheimer’s treatment have increased the need for precise diagnostics in the field. Researchers in Uppsala are working to develop improv...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.